SELLAS Life Sciences Group (NASDAQ:SLS) Posts Earnings Results, Beats Expectations By $0.01 EPS

SELLAS Life Sciences Group (NASDAQ:SLS) released its earnings results on Tuesday. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01, FiscalAI reports.

SELLAS Life Sciences Group Price Performance

Shares of SLS stock traded up $0.61 during trading hours on Wednesday, hitting $5.83. The stock had a trading volume of 11,518,316 shares, compared to its average volume of 7,298,396. The firm has a market capitalization of $1.08 billion, a PE ratio of -23.41 and a beta of 2.24. SELLAS Life Sciences Group has a twelve month low of $1.39 and a twelve month high of $6.72. The stock’s 50 day moving average is $4.95 and its 200 day moving average is $3.64.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on SLS shares. Weiss Ratings restated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Tuesday, April 21st. Maxim Group upped their price target on SELLAS Life Sciences Group from $7.00 to $10.00 and gave the company a “buy” rating in a report on Thursday, March 12th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, SELLAS Life Sciences Group has a consensus rating of “Hold” and an average target price of $10.00.

Institutional Investors Weigh In On SELLAS Life Sciences Group

Large investors have recently modified their holdings of the company. BNP Paribas Financial Markets boosted its holdings in shares of SELLAS Life Sciences Group by 89.2% in the third quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company’s stock valued at $32,000 after acquiring an additional 9,299 shares during the period. Beacon Pointe Advisors LLC acquired a new stake in shares of SELLAS Life Sciences Group during the fourth quarter worth $38,000. Sei Investments Co. acquired a new stake in shares of SELLAS Life Sciences Group during the third quarter worth $43,000. Great Valley Advisor Group Inc. acquired a new stake in shares of SELLAS Life Sciences Group during the second quarter worth $44,000. Finally, Equitable Holdings Inc. lifted its holdings in shares of SELLAS Life Sciences Group by 58.6% during the third quarter. Equitable Holdings Inc. now owns 27,060 shares of the company’s stock worth $44,000 after purchasing an additional 10,000 shares during the period. 17.38% of the stock is owned by institutional investors and hedge funds.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.